Kornimate/medical-research-clean huggingface dataset:
clinical evaluation of implants restored with advanced lithium disilicate screw-retained crowns

Conditions: Dental Prosthesis Failure; Dental Prosthesis Complication

Summary: this is a prospective observational clinical trial to evaluate the clinical performance of the cerec tessera prosthetic assembly on implants restored with chairside cad/cam-generated crowns. this investigation is intended as a post market clinical follow-up study for the product cerec tessera and its prosthetic assembly for implants, which will serve as a life-cycle approach to safety, backed up by clinical data and post-market monitoring.


Eligibility criteria:
inclusion criteria: * adults aged 18-75 years. * willing and able to sign and date the informed consent form and hipaa form. * have a single implant that has been successfully osseointegrated and deemed ready for restoration by the surgeon placing the implant. (a maximum of two single dental implant restorations per subject will be restored.) * have a single implant that is acceptable to be restored with a digital workflow using the cerec system. * have a single implant to be restored with a screw retained advanced lithium disilicate crown. * have a single implant with at least one adjacent tooth contact and with an occlusal contact. exclusion criteria: * not willing to participate in the clinical investigation or not able to understand the content of the clinical investigation. * unlikely to be able to comply with clinical investigation procedures according to the principle investigator's/co-investigator's judgement. * unable or unwilling to return for recall appointments for a period of 5 years. * severe non-compliance to clinical investigation protocol as judged by the pi or co-investigators. * women who self-report that they are possibly pregnant, pregnant, or lactating, as elective dental treatment is not indicated at these times. * previous enrollment in the present clinical investigation. * involvement in the planning and conduct of the clinical investigation (applies to both dentsply sirona personnel and from the clinical investigation site).
a two-part multiple dose study to assess the safety and effects of azd3293 in healthy elderly and alzheimer's patients

Conditions: Healthy Elderly Volunteers; Mild-to-moderate Alzheimer's Disease Patients

Summary: this is a two-part multiple dose study in healthy male and female (of non-child bearing potential) elderly volunteers, and in alzheimer's disease patients, to assess the safety, effects on the body, and blood, csf, and urine drug levels of azd3293. azd3293 is being developed for the treatment of alzheimer's disease

a phase i, randomized, double-blind, placebo-controlled, two-part, multiple ascending dose study to assess the safety, tolerability, pharmacokinetics and effect on biomarkers of azd3293 in plasma and cerebrospinal fluid in healthy male and non-fertile female elderly volunteers and in mild-to-moderate alzheimer disease patients

Eligibility criteria:
inclusion criteria: * part 1: healthy elderly male and female (of non-childbearing potential) subjects. * part 2: male and non-fertile female ad patients. * body mass index (bmi) between 19 and 30 kg/m2 and weigh at least 50 kg and no more than 100 kg. * part 2: clinical diagnosis of probable ad according to the nincds-adrda criteria. * part 2: manifestation of ad symptoms at least 6 months before randomization. exclusion criteria: * part 1: history or presence of psychiatric disease/condition, gi, renal, hepatic, cardiovascular, psychiatric, or retinal diseases or disorders. * part 2: significant disease affecting the cns other than alzheimer's disease, including but not limited to other dementias, other significant neurological or major psychiatric disease. * history of use of antipsychotic drugs , or chronic use of antidepressant or anxiolytic drugs. * frequent use (more than 2 days per week during the last 12 weeks) of tobacco or other nicotine products. * history of neurological disease, including seizures, recent memory impairment, or clinically significant head injury.

Keywords: azd3293 healthy volunteers elderly volunteers alzheimer's disease patients ad patients phase 1 multiple ascending dose study
effect of covid-19 infection on the performance of adolescent professional overhead athletes

Conditions: COVID-19; Sport Performance, Professional Overhead Athletes

Summary: covid-19 is known to also cause damage outside the pulmonary system, particularly the cardiovascular and the musculoskeletal system. the studies on the effects of covid-19 infection on different populations may provide valuable information for health professionals. derangements in the cardiorespiratory and musculoskeletal systems which normally direct effect on the sports performance of athlete together with physical inactivity during covid-19 infection are the main factors that may decrease the performance of the professional athletes. although it may be well anticipated that covid-19 will reduce sports performance; there are scarce studies in the literature. the aim of this study is to compare the sports performance of adolescent athletes that has covid-19 infection with those did not.

extensor muscle endurance, flexor muscle endurance and the lateral core muscle endurance were evaluated. all tests were performed by a chronometer and test was terminated as the position was lost and the time passed was recorded. hand grip strength was measured by jamar hand dynamometer. health ball throwing test was used to evaluate upper extremity open kinetic chain and explosive power. pro-agility test was used to evaluate the agility. step test was performed for 3 minutes with a 30 cm high step board.

Eligibility criteria:
inclusion criteria: * basketball, volleyball, handball, tennis and american football players * between 12 to 20 * performing sports-specific training more than two times a week at least for 1 year exclusion criteria: * vertebral, upper or lower extremity injury within the last 6 weeks or had undergone a surgery

Keywords: covid-19 sport performance adolescent athletes overhead sport
a research study looking at how the compound nnc0487-0111 works with birth control pills and affects emptying of the stomach in women not able to become pregnant

Conditions: Obesity

Summary: this study medicine nnc0487-0111 to improve the treatment options for people living with overweight and obesity or with type 2 diabetes. the purpose of the study is to investigate if nnc0487-0111 affects how effective birth control pills are. participants will take 1-tablet once daily. the study medicine will taken orally for 18 weeks and then study medicine will be injected with a thin needle in a skin fold in the abdomen for 9 weeks.the study will last for about 35 weeks.


Eligibility criteria:
inclusion criteria: * females of non-childbearing potential. * age 18 - 65 years (both inclusive) at the time of signing the informed consent. * body mass index (bmi) between 25.0 and 39.9 kg/m\^2 (both inclusive) at screening. * considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. exclusion criteria: * any disorder, unwillingness or inability which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. * any contraindications for the use of the oral contraception used in the study according to the microgynon product information. * use of prescription medicinal products or non-prescription drugs including any herbal medicine known to interfere with the metabolic cyp pathways, such as hypericum (st. john's wort), ginseng, garlic, milk thistle, and echinaceae, within 14 days before screening. exceptions are routine vitamins, occasional use of acetaminophen, ibuprofen and acetylsalicylic acid, or topical medication not reaching systemic circulation. * history of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant. * presence of clinically significant gastrointestinal disorders potentially affecting absorption of drugs or nutrients, as judged by the investigator.
ehealth evidence-based intervention (ebi) for latino youth in primary care

Conditions: Sexual Risk Behavior; Drug Use; Family Functioning

Summary: the purpose of this study is to test the relative effectiveness of a hispanic-specific ehealth intervention, "e-health familias unidas," in preventing and reducing drug use, sexual risk behaviors, and stis among hispanic youth in primary care. families will be recruited through four pediatric primary care settings. pediatric staff and research team members, including nurse assistants and mental health professionals, will implement ehealth familias unidas.


Eligibility criteria:
inclusion criteria: * female and male adolescents of hispanic immigrant origin, defined by at least one parent born in a spanish speaking country of the americas. parent must understand spanish given that parent sessions are delivered in spanish. * adolescent between the ages of 12 - 17 years * adolescent living with an adult primary caregiver who is willing to participate * families must have broadband internet access on a device, including (but not limited to) a smart phone, ipad, tablet, a home computer or a computer at another location (e.g., school, library, etc.) exclusion criteria: * families reporting plans to move out of the south florida area during the study period * families reporting that adolescent has been diagnosed with a developmental delay

Keywords: prevention with hispanic youth ehealth preventive intervention in primary care hispanic adolescent familias unidas ehealth familias unidas effectiveness trial sexually transmitted disease parent-centered hispanic sexual risk behavior
benefit of septifast multiplex pcr in the etiologic diagnosis and therapeutic approach for onco-hematology patients presenting sepsis

Conditions: Hematologic Diseases; Sepsis

Summary: a spetifast multiplex pcr kit has recently been placed on the market witch can evidence the dna of 90% of micro-organisms (bacteria and fungus) implicated in sepsis. however, the clinical impact of being able to detect the dna of these various agents is unknown. we propose to assess the benefit to patient care of the septifast multiples pcr by answering three questions : 1/in patients with septic immunosuppression, does this kit evidence etiologic agents not revealed by classical methods? 2/does the use of pcr results permit different diagnostic hypotheses to be considered? 3/does having the septifast results entail changes to the therapeutic plan?

this study has double purpose : 1. to compare the results obtained from the septifast system with the results from classical microbiological sampling, in particular hemoculture, for immunosuppressed patients presenting sepsis. 2. to perform a blind assessment of the benefit of septifast care of these patients.

Eligibility criteria:
inclusion criteria: all patients with onco-hematologic or cancerous pathology, or hematologic disease with chemotherapy and/or radiotherapy and/or some other immunosuppressant treatment in progress presenting an infection requiring hospitalisation and meeting the following criteria: * sepsis (at least one of the following signs): * fever \> 38.2°c or hypothermia \< 36°c * fo120 min * pa\<120 mmhg (or 50 mmhg reduction in base numbers) * respiratory f \> 30/min * confusion * hyperleucocytosis (\>12 g/l) or leucopenia (\<4 g/l) * c-reactive protein \> 40 * with or without organ dysfunction as defined by : * hypoxia (pao2/fio2\<300mmhg) * oliguria (urine deficiency\<0.5 ml/kg/h in probed patient) * creatinine \> 200umol/l * inr\>1.5 or tca\>2 x control in the absence of anticoagulant treatment * platelets \< 100 g/l * bilirubin \> 35 umol/l * lactatemia \> 2 mmol/l * arterial hypotension (pas\<90mmhg, or pam\<70mmhg or reduction of more than 40 mmhg if known hypertension) exclusion criteria: * minor patient * pregnancy * a patient cannot be included again within 15 days of his/her preceding inclusion

Keywords: sepsis immunosuppressed multiplex pcr diagnosis therapeutic
phase 1-2 of temozolomide and hypofractionated radiotherapy in tx of supratentorial glioblastoma multiform

Conditions: Glioblastoma; Cancer of Brain and Nervous System; Glioblastoma Multiforme

Summary: the purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy plus the fda-approved chemotherapy drug temozolomide

primary objective: to determine the maximum tolerated dose (mtd), based on acute cns toxicity at 30 days, of hypofractionated radiotherapy given in 5 fractions with temozolomide for the treatment of glioblastoma multiforme. secondary objectives: 1. assess the short- and long-term adverse effects. 2. determine the radiographic response rate. 3. determine the overall survival rate. 4. assess quality of life during treatment to determine the maximum tolerated dose (mtd) of hypofractionated (5 fractions) radiotherapy with temozolomide for the treatment of glioblastoma multiforme, patients will be evaluated by a multi-disciplinary team composed of radiation oncologists, neurosurgeons, and neuro-oncologists to assess for their eligibility. patient's oncologic history, presenting symptoms, physical examination, pathology, and imaging studies will be reviewed. patients will be evaluated for surgical candidacy and resectability. patients who are surgical candidates will undergo a surgical resection prior to radiotherapy. patients whose tumors are unresectable or are not good surgical candidates will undergo a biopsy for tissue diagnosis. radiation will be delivered in five fractions.

Eligibility criteria:
inclusion criteria: * histopathologically confirmed newly diagnosed glioblastoma multiforme. diagnosis must be made by surgical biopsy or excision * the tumor must be supratentorial in location * the planning target volume (tumor plus margin) must measure ≤ 150 cm\^3 in volume * age ≥ 18 years * life expectancy of at least 12 weeks * patient must have adequate organ function to tolerate temozolomide (details in the protocol) exclusion criteria: * patients who have previously been treated with brain irradiation to the region that would result in overlap of the radiation fields * tumor foci detected below the tentorium * multifocal disease or leptomeningeal spread * prior allergic reaction to the study drugs involved in this protocol * patients with pacemaker will be allowed to undergo ct instead of mri * pediatric patients (age \< 18), pregnant women, and nursing patients will be excluded
optimizing the evaluation of awareness in disorders of consciousness

Conditions: Disorders of Consciousness

Summary: the purpose of this study is to evaluate whether personalized stimulations can improve the detection of electrophysiological signs of awareness in patients with disorders of consciousness.


Eligibility criteria:
inclusion criteria: * patients in a vegetative state or a minimally conscious state * agreement from families exclusion criteria: * patients with akinetic mutism or locked-in syndrome * patients in a coma * patients with damages in the inner or middle ear * contraindication to a high-density electroencephalography exam
a study of the efficacy and safety of albiglutide in subjects with type 2 diabetes with renal impairment.

Conditions: Diabetes Mellitus, Type 2

Summary: this randomized, double-blind, active-controlled study evaluates the efficacy and safety of a weekly dose of albiglutide as compared with sitagliptin. subjects who are renally impaired with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately controlled on their current regimen of diet and exercise or their antidiabetic therapy of metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetic medications will be recruited into the study.

this randomized, double-blind, active-controlled, 2 parallel-group, multicenter study evaluates the efficacy and safety of a weekly subcutaneously injected dose of albiglutide as compared with sitagliptin. subjects who are renally impaired with a historical diagnosis of type 2 diabetes mellitus and whose glycemia is inadequately controlled on their current regimen of diet and exercise or their antidiabetic therapy of metformin, thiazolidinedione, sulfonylurea, or any combination of these oral antidiabetic medications will be recruited into the study.

Eligibility criteria:
inclusion criteria: * renally impaired with a historical diagnosis of type 2 diabetes mellitus and is experiencing inadequate glycemic control on their current regime of diet and exercise or their antidiabetic therapy of metformin, tzd, su, or any combination of these oral antidiabetic medications * bmi \>/=20 kg/m2 and \</=45 kg/m2 * fasting c-peptide \>/=0.8 ng/ml (\>/=0.26 nmol/l) * hba1c between 7.0% and 10.0%, inclusive. exclusion criteria: * history of cancer * history of treated diabetic gastroparesis * current biliary disease or history of pancreatitis * history of significant gastrointestinal surgery * recent clinically significant cardiovascular and/or cerebrovascular disease * history of human immunodeficiency virus infection * abnormal liver function or acute symptomatic infection with hepatitis b or hepatitis c * female subject is pregnant (confirmed by laboratory testing), lactating, or \<6 weeks postpartum * known allergy to any glp 1 analogue, sitagliptin, other study medications' excipients, excipients of albiglutide, or baker's yeast * receipt of any investigational drug or sitagliptin within the 30 days or 5 half lives, whichever is longer, before screening or a history of receipt of an investigational antidiabetic drug within the 3 months before randomization or receipt of albiglutide in previous studies

Keywords: sitagliptin albiglutide renal impairment
the thickness of the muscles and pain in impingement syndrome

Conditions: Impingement Shoulder; Impingement Syndrome; Pain, Shoulder

Summary: pain intensity will be measured with visual analog scale. sonographic severity grade of shoulder impingement syndrome, serratus anterior muscle, upper trapezius and middle trapezius will be measured with usg in patients diagnosed with impingement and meeting the criteria and healthy volunteers.

patients diagnosed with impingement and meeting the criteria will be included, while the healthy group will consist of hospital staff who do not have shoulder pain and who are not diagnosed with a shoulder-related disease. pain intensity will be measured with vas (visual analog scale), the sonographic severity grade of shoulder impingement syndrome, the serratus anterior muscle, the upper trapezius and the middle trapezius will be measured with usg.

Eligibility criteria:
inclusion criteria: * 18-65 years * cognitive ability to understand test instructions * symptom duration longer than 1 month * at least two positive neer, hawkins and painful arch tests for healty volunteers * 18-65 years * cognitive ability to understand test instructions * negative impingment test exclusion criteria: * fibromyalgia * cervical radiculopathy * those who have received injections or physical therapy in the last month * those with a disorder that may affect shoulder joint range of motion and muscle mass (previous fracture, surgery, subluxation) * bmi over 35 * inflammatory disease
local metformin gel and impacted lower third molar

Conditions: Impacted Third Molar Tooth

Summary: * completed medical and dental history will take for all patients and the position of the impacted teeth will evaluate by panoramic films. patients will fully inform about the treatment procedures, follow-up examinations and complications of surgical procedures. * the study will be carried out as a randomized controlled clinical trial. randomly, by the use of predefined computer-generated randomization table, the eligible patients will be randomized in equal proportions between study group: patients will receive 1% metformin gel in the socket following removal of the impacted third molar and control group: patients will receive placebo gel 2% hydroxymethyl cellulose.all surgeries will be performed under complete aseptic conditions. before surgery, the patient's mouth will be rinsed with a chlorhexidine digluconate solution 0.2% for 2 minutes. surgery will carry out under local anesthesia consisting of 4% articain hydrochloride with 1:100,000 adrenaline. * full thickness mucoperiosteal flap will be raised to expose sufficient bone on lateral and distal aspect of the impacted molar. removal of bone will be done with stainless steel bur under constant irrigation with normal saline while removing bone to prevent thermal necrosis. * when necessary, sectioning of crown and roots will be performed with a fissure bur. after tooth extraction, the alveolus will be inspected, curetted, and irrigated with 0.9% sterile saline solution. * surgical removal of impacted mandibular third molar will be done,1% metformin gel or placebo gel in the socket following removal of the impacted third molar . * the mucoperiosteal flap will be repositioned and sutured with 3-0 black silk suture.


Eligibility criteria:
inclusion criteria: * • age ≥18ys * no systemic disease * impacted mandibular third molar class ii position b on pell- gregory classification exclusion criteria: * • history of metabolic or systemic diseases affecting bone or healing process, * local infection, * tobacco use, * oral contraceptive, * pregnancy and lactation * patients who had taken analgesics or anti-inflammatories for 1 week prior to enrollment in the study
acute effects of static stretching intensity and duration on muscle viscoelastic properties and proprioception

Conditions: Static Stretching

Summary: the purpose of this study is to compare the acute effects of different duration and intensity of static stretching exercises on the viscoelastic properties of the hamstring muscle and the knee proprioception.

traditionally stretching exercises have been used by health professionals as a means of preventing injuries by increasing performance and increasing joint flexibility. kubo et al. suggest that the potential mechanism of decreased risk of injury with increased flexibility is a change in the viscoelastic properties of the muscle-tendon unit. muscle fibers and tendons contain proprioceptors. these receptors provide information about joint angle, muscle length and muscle tension. there are two stretch-related proprioceptors that transmit information to the central nervous system about muscle tension. these receptors are muscle spindles (respond to changes in the length) and golgi tendon organs (respond to changes in the tension). for this reason, interactions between muscle tension, muscle-tendon unit, viscoelasticity and proprioceptive tissue (muscle spindles and golgi tendon organ); it becomes important when you think about how stretching exercises affect proprioception, flexibility and increase or decrease of joint range of motion. in the literature, four stretching parameters have been defined as important to influence the potential for increasing or decreasing the flexibility of a joint: intensity, duration, frequency and stretching position. the focus of this study we plan on is the intensity and duration of stretching. exercise warming exercises before sportive activity and cooling exercises afterwards are widely suggested and applied. determining the relationship between stretch severity and duration and viscoelastic properties and proprioception will contribute to the effective creation of training programs.

Eligibility criteria:
inclusion criteria: * being in the 18-45 age range. * volunteer to participate in the study. exclusion criteria: * having had previous lower extremity operations. * having an orthopedic, neurological and rheumatologic disease of the lower extremities. * having open wound in the application area. * having had soft tissue injury in the last 6 weeks in the application area.

Keywords: static stretching stiffness proprioception healthy adults